ENDPOINTS

Denali stops some work on ALS drug after analysis showed no impact on key biomarker

Denali Therapeutics’ ALS program showed no effect on an important neurodegeneration biomarker that could have been used for FDA approval after a failed topline readout earlier this year. The company is discontinuing DNL343 in that ...

Mar 6, 2025 - 15:51
 0
Denali stops some work on ALS drug after analysis showed no impact on key biomarker
Denali Therapeutics’ ALS program showed no effect on an important neurodegeneration biomarker that could have been used for FDA approval after a failed topline readout earlier this year. The company is discontinuing DNL343 in that ...
Read More

Tags:

Previous Article

Why This Year’s Flu Season Is the Worst in More Than a Decade

Next Article

Highly expressive ancient puppets found in Salvadorian pyramid

Related Posts

Pacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai and CRISPR Therapeutics

Pacira absorbs GQ Bio for $32M; Layoffs at BMS, Eisai a...

Feb 28, 2025  0

Hims buys at-home testing company Trybe Labs

Hims buys at-home testing company Trybe Labs

Feb 19, 2025  0

Where the money is: The top 100 venture investors in biotech

Where the money is: The top 100 venture investors in bi...

Feb 25, 2025  0